Moderna (MRNA) Asset Utilization Ratio (2019 - 2026)
Moderna (MRNA) posted quarterly Asset Utilization Ratio of 0.2 for Q2 2026, down 20.31% year-over-year from 0.25 in Q2 2025, and up 6.28% on a QoQ basis from 0.19 in Q1 2026.
Moderna (MRNA) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Moderna has reported Asset Utilization Ratio for 8 years, with the latest figure at 0.2 in Q2 2026.
- Asset Utilization Ratio for Q2 2026 came in at 0.2, down 20.31% year-over-year; the trailing twelve-month figure through Jun 2026 was 0.2 (down 20.31% YoY), and the FY2025 annual result was 0.15, down 26.11% from the prior year.
- Asset Utilization Ratio climbed to 0.2 in Q2 2026, from 0.19 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.86 in Q1 2022 and troughed at 0.16 in Q4 2025.
- A 5-year average of 0.42 and a median of 0.32 in 2024 frame the typical range for Asset Utilization Ratio.
- The widest annual swing landed in 2022, when Asset Utilization Ratio soared 216.97%; it then plunged 51.35% in 2024.
- A 5-year view of Asset Utilization Ratio shows it stood at 0.74 in 2022, then slumped by 51.27% to 0.36 in 2023, then tumbled by 40.23% to 0.22 in 2024, then retreated by 26.49% to 0.16 in 2025, then gained by 24.94% to 0.2 in 2026.
- Per Business Quant data, the three most recent Asset Utilization Ratio figures were 0.2 in Q2 2026, 0.19 in Q1 2026, and 0.16 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 0.13 |
| 10 | Roivant Sciences | 26.25 Bn | 26.25 Bn | 1.16 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.20 |
| Mar 31, 2026 | 0.19 |
| Dec 31, 2025 | 0.16 |
| Sep 30, 2025 | 0.18 |
| Jun 30, 2025 | 0.25 |
| Mar 31, 2025 | 0.24 |
| Dec 31, 2024 | 0.22 |
| Sep 30, 2024 | 0.32 |
| Jun 30, 2024 | 0.31 |
| Mar 31, 2024 | 0.29 |
| Dec 31, 2023 | 0.36 |
| Sep 30, 2023 | 0.44 |
| Jun 30, 2023 | 0.46 |
| Mar 31, 2023 | 0.60 |
| Dec 31, 2022 | 0.74 |
| Sep 30, 2022 | 0.82 |
| Jun 30, 2022 | 0.86 |
| Mar 31, 2022 | 0.86 |
| Dec 31, 2021 | 0.81 |
| Sep 30, 2021 | 0.64 |